Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2006
Business Overview: BMS is a global pharmaceutical and health care products company organized into three reportable segments: Pharmaceuticals, Nutritionals, and Other Health Care. The company focuses on the discovery, development, and commercialization of pharmaceuticals and related health care products.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2006 | Q1 2005 |
|---|---|---|
| Net Sales | $4,676 | $4,532 |
| Cost of Products Sold | $1,476 | $1,367 |
| Gross Margin % | 68.4% | 69.8% |
| Research & Development | $750 | $653 |
| Earnings from Continuing Ops (Pre-tax) | $1,193 | $928 |
| Net Earnings | $714 | $533 |
| Diluted EPS | $0.36 | $0.27 |
| Operating Cash Flow | $83 | $783 |
| Cash & Cash Equivalents (End of Period) | $2,477 | $3,311 |
| Long-term Debt | $8,278 | $8,364 |
| Working Capital | $5,584 | $5,393 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 3% to $4.676 billion, driven by a 14% increase in U.S. sales, partially offset by an 8% decline in international sales due to foreign exchange impacts and generic competition.
- Profitability: Net earnings rose 34% to $714 million. Earnings from continuing operations before taxes increased 29% to $1.193 billion.
- One-Time Items:
- Gain on Sale: A $200 million pre-tax gain was recognized from the sale of the DOVONEX* product asset to Warner Chilcott.
- Litigation: Litigation income of $21 million was recorded in 2006 (insurance recovery), compared to $124 million in charges in 2005.
- Milestone Payments: A $250 million milestone payment was made to ImClone for FDA approval of ERBITUX* for head and neck cancer.
- Accounting Changes: Adoption of SFAS No. 123(R) resulted in the recognition of $37 million in stock-based compensation expense, compared to $9 million in the prior year.
- Cash Flow: Operating cash flow decreased significantly to $83 million from $783 million, primarily due to higher working capital usage, litigation settlement payments ($247 million), and tax payments.
Guidance, Outlook, and Risks
- Exclusivity Losses: Management estimates net sales reductions of $1.4 billion to $1.5 billion in 2006 compared to 2005 levels due to lost market exclusivity for products such as PRAVACHOL, TAXOL, and CEFZIL.
- Investment Plans: The company announced a $200 million investment to expand its Manati, Puerto Rico facility and a planned $660 million investment for a new biologics manufacturing facility in the U.S.
- Key Risks:
- PLAVIX* Litigation: A proposed settlement with Apotex regarding patent infringement is pending antitrust clearance. If the settlement fails, generic competition could launch at risk, materially impacting sales of the company's largest product.
- Legal Proceedings: Significant pending litigation includes pricing practices (AWP), product liability (SERZONE, HRT), and environmental matters. Management believes the aggregate impact beyond current reserves could be material.
- Regulatory: Ongoing investigations by the SEC and U.S. Attorney's Office regarding wholesaler inventory and accounting practices remain under a Deferred Prosecution Agreement.
Investor Verification Checklist
- PLAVIX* Settlement Status: Verify the outcome of the antitrust review for the Apotex settlement and the potential for generic entry in 2006.
- Exclusivity Impact: Monitor actual sales declines for PRAVACHOL, TAXOL, and CEFZIL against the $1.4–$1.5 billion guidance range.
- Legal Reserves: Review updates on pricing litigation (AWP) and product liability cases (SERZONE, HRT) to assess if current reserves ($146 million for pricing, $75 million for SERZONE) remain adequate.
- Biologics Pipeline: Track the progress of ORENCIA and the timeline for the new biologics manufacturing facility to ensure capacity meets demand.
- Stock-Based Compensation: Assess the ongoing impact of SFAS 123(R) on future operating margins as stock option expensing continues.